Ironwood Pharmaceuticals (IRWD) : Traders are bullish on Ironwood Pharmaceuticals (IRWD) as it has outperformed the S&P 500 by a wide margin of 20.41% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.85%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.02% in the last 1 week, and is up 19.76% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.79% and the 50-Day Moving Average is 12.49%.The 200 Day SMA reached 34.37%
Ironwood Pharmaceuticals (NASDAQ:IRWD): After opening at $15.54, the stock dipped to an intraday low of $15.17 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $15.93 and the buying power remained strong till the end. The stock closed at $15.88 for the day, a gain of 3.12% for the day session. The total traded volume was 992,558. The stocks close on the previous trading day was $15.88.
Ironwood Pharmaceuticals (IRWD) : 8 investment research analysts covering Ironwood Pharmaceuticals (IRWD) have an average price target of $15.38 for the near short term. The highest target price given by the Brokerage Firm to the stock is $24 and the lowest target is $10 for the short term. Analysts expect the variance to be within $4.5 of the average price.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.